(Makor) Europe Real Estate - View & Trading Ideas (full note attached)

SUMMARY OF TRADE/INVESTMENT IDEAS: Our last call to exit European real estate stocks and even go short vs. the Euro Stoxx, against general consensus, proved to be correct as the sector underperformed the European index by almost 9%. We still recommend to underweight the sector and favor hedged strategies in the sector. Real estate stocks are generally overvalued in absolute terms, and fair value to overvalued relative to interest rates, although selected long opportunities to exist. Within the interest rate sensitive sectors, banks remain a lot more attractive. We take this opportunity to mention that our best call in the sector was going long Eurobank Properties, a major Greek real estate company, at the worst of the Greek crisis last year. At the time, the company was not only net cash for more than a third of its market cap, but enjoyed a rental income yield of more than 37% and a discount to NAV in excess of 60%. A bit more than a year later, the shares have tripled and are now selling on a premium of almost 20%. Needless to say that the shares are now overvalued…

1. LONG/SHORT MACRO/SECTORAL TRADES - SHORT IUKP LN / LONG FTSE FUT / LONG GILT FUT: this is the preferred trade structure with hedge ratio 1:1:1. Other trade structures are short IUKP LN / long FTSE 1:1, and short IUKP / long Gilts 1:2 - SHORT IUKP LN / LONG EEE FP 2. LONG/SHORT RELATIVE VALUE/MEAN REVERTING PAIRS - LONG SHB LN / SHORT GPOR LN – short bias - LONG INTU LN / SHORT IUKP LN - LONG CORA NA / SHORT UN NA – long bias 3. LONG ONLY (MKT CAP > $1BN) INTU LN; SGRO LN; SBD LN; LI FP; GFC FP; FDR FP; MERY FP; FMU FP; CORA NA; AOX GR; ALLN SW; MLSR IT 4. SHORT ONLY (MKT CAP > $1BN) GRPO LN; SHB LN; DLN LN; IUKP LN 5. SPECIAL SITUATIONS NISTI NA; IGD IM

>>> Mozambique's ENH seeks to boost its stakes in Rovuma gas fields operated by

Mozambique's ENH seeks to boost its stakes in Rovuma gas fields operated by Eni and Anadarko

Mozambique's ENH national hydrocarbons company wants to increase its stakes in offshore gas fields operated by Eni and Anadarko, reported Club of Mozambique. The news service cited ENH projects director Paulino Gergorio as saying the state group is examining ways to boost its holdings in the respective Rovuma basin holdings.

Mozambique plans to build four liquefied natural gas LNG trains with a combined 20 million tonnes capacity by 2018 in a project valued at up to USD 20bn. Several banks have contacted ENH over financing of its stake in this project, said Gregorio without naming these potential lenders.

Source Club of Mozambique

FT : KPMG treads new ground with fund

KPMG treads new ground with fund

KPMG, the giant professional services company, will on Monday launch its first investment fund as it branches out into other areas in a sign of the big changes afoot in the financial services industry. The move is significant as the fund will invest in data and analytics businesses, which are increasingly popular with investors as technology is considered a growth area that should benefit from economic recovery.

The group, one of the big four professional services companies employing 152,000 people around the world in 156 countries and with combined revenues of $23bn, is creating KPMG Capital, a new wholly owned fund. Mark Toon, chief executive of the new fund, said: “With more data produced and stored in the last two years than in the rest of human history, many businesses are looking for strategic and practical solutions to manage the volume, velocity and variety of this data revolution.” KPMG, which is a tax, auditing and advisory firm, has decided to diversify to use its expertise around the world to build a business in data and analytics. The fund, which could be the first of many, will launch with about $100m. It will invest primarily in data and analytics businesses through strategic acquisitions, technology partnerships and other data and analytics capabilities. The move follows last month’s announcement by Deloitte, another of the big four professional services firms, that it is buying Seattle-based social media marketing agency Banyan Branch for an undisclosed sum. Deloitte’s acquisition is another example of how these big groups are looking to take advantage of the rapid changes in technology, social media and data provision. The KPMG fund will have its headquarters in London and invest globally. It aims to invest in a number of critical business areas including enhancing business flexibility; finance; risk, regulation and compliance; improving workforce productivity; and customer and revenue growth. The new fund will also co-invest, sponsor and partner other groups at early stages with the aim to encourage entrepreneurs to be bold, focusing on growth sectors such as healthcare, financial services, energy and telecommunications. Separately, KPMG/Markit launched its first report on technology last month. This report will be produced quarterly, analysing UK tech clusters and tracking the sector’s outlook for employment and growth. The new fund will not be open to third-party investment.

FT : Shire buys US drugs group ViroPharma for $4.2bn

Shire buys US drugs group ViroPharma for $4.2bn

Shire, the London-listed pharmaceuticals group, has moved to bolster its rare disease portfolio with the acquisition of ViroPharma for $4.2bn. Ireland-domiciled Shire will pay $50 a share in cash for all the outstanding shares of ViroPharma, representing a 27 per cent premium to the Pennsylvania-based company’s closing price on Friday and a 64 per cent premium to the shares before talk of the transaction surfaced in September.

The move is part of the so-called One Shire programme initiated by new chief executive Flemming Ornskov. It emerged last week that the group was discussing substantial cuts among its 170 research scientists at its historic headquarters in Basingstoke. It is also looking at moving its Swiss office from Nyon to Zug and refocusing US operations close to Boston. The ViroPharma transaction adds to Shire’s portfolio Cinryze, a preventive injectable treatment for hereditary angioedema, which causes sudden attacks of swelling. Shire already has an acute treatment for the condition, Firazyr, which can be injected when sufferers sense an imminent attack. Shire expects the addition of Cinryze to its rare disease unit to create a business with revenues of $2bn in 2014, which would represent about 40 per cent of Shire’s sales on a pro forma basis. Mr Ornskov said: “The acquisition of ViroPharma will immediately benefit Shire and is entirely consistent with our clear strategic objective of strengthening our rare disease portfolio. It brings us a new growth driving product which augments our already strong growth prospects.” Shire said the proposed deal, which was still subject to approvals, would generate cost synergies of about $150m by 2015. Shares in Shire opened up 1 per cent at £28.27 in early London trading on Monday.

>>> Activist funds hunt for European targets

Cash-rich US activists are setting their sights on Europe. Bill Ackman, founder of New York-based Pershing Square Capital, said last month: "Europe is probably 10 years behind [the US] in terms of the degree of shareholder activism and how directors respond and precedent and so on so I think it’s harder here but I think it’s going to happen." Ackman was speaking to MBA students at Oxford’s Saïd Business School.

Gilberto Pozzi, head of European M&A at Goldman Sachs, said: "US activists are likely to target European opportunities in the short to medium term."

Nine of the 10 largest activist campaigns outside the US since 2012 have taken place in Europe, and were backed by renowned US activists such as Nelson Peltz’s Trian Partners and Carl Icahn. Last year Paul Singer’s US-based Elliott Associates pushed the UK’s BMC Software to put itself up for sale, and recently Elliott built up a stake in Kabel Deutschland in an effort to put pressure on Vodafone to bid a higher price.

Positive headwinds for activists have included rising equity markets, and a better environment for stock-picking and mergers and acquisitions.

Now activists are targeting multi-segment firms. The global conglomerate discount has widened from 5.5% in 2010 to 7.4% currently, and is at the highest among European companies at 9.3%, suggesting that diversified companies in Europe might be more vulnerable than their peers in other parts of the world, according to a report from Citigroup last month called "Rising tide of global shareholder activism".

Activist hedge funds have gained almost 20% a year since 2009, compared with 7.5% for hedge funds as a whole, according to Citi. Activist strategies are up 11.9% this year through September – more than double that of the average hedge fund, according to data provider Hedge Fund Research. Some individual funds have fared even better: Knight Vinke’s Europe-focused activist fund is up 24.7% this year through October, according to a person familiar with the firm.

As a result of this outperformance, money has poured into the sector, allowing funds to increase the size of their targets and fuelling the pace of campaigns. Assets run by activist strategies have grown from $36.2 billion at the end of 2009 to $89.1 billion at the end of the third quarter this year, HFR said. Since 2009, the number of campaigns targeting firms of $10 billion and larger has more than tripled, and 2013 has seen an average of two such large-cap firms targeted every month, said Citi.

On top of this, there is greater institutional support for activism. Harlan Zimmerman, senior partner at Anglo-Swedish operational activist Cevian Capital, said: "The financial crisis was seen as a failure of ownership by boards and shareholders. This created huge pressure on institutions to be better owners."

Following the financial crisis, politicians such as former City minister Lord Myners, who is now chairman of Cevian, accused investors of allowing "ownerless corporations", to develop, and failing to check poor governance. Professor John Kay’s report on long-term governance, published in July 2012, advocated that investors band together to improve governance. Passive managers such as L&G, BlackRock and Norges Bank are engaging on corporate governance issues behind the scenes.

Blake Nixon, founding partner of UK activist Worsley Associates, which launched this year, said: "Having institutional investors who are private supporters is an important factor in convincing a company to engage."

One of the issues preventing more outright activism in Europe is a lack of players willing to take it on. Dan Mannix, chief executive of RWC Partners, which runs three activist funds, said: "There has been a real lack of decent activist investors in Europe because it’s a very difficult market. You have to deal with multiple jurisdictions with different operating environments, languages and shareholder structures. It also requires a significant amount of scale."

The biggest players in Europe by assets are Cevian, which runs $12 billion, and has in the past three months revealed stakes in UK security company G4S, and ThyssenKrupp, a German industrials company; and Chris Hohn’s The Children’s Investment Fund, which runs $7 billion and is perhaps best known for pushing for a break-up of ABN Amro. This year TCI has been calling for French aerospace manufacturer EADS to sell its stake in rival Dassault.

European event-driven funds – the so-called "part-time activists" with a shorter-term time horizon, which pushed companies to pay out jumbo dividends in the run-up to the financial crisis – have largely retreated as a result of performance issues during 2008 and a lack of stable capital in their investor base.

Within Europe, activists are most likely to target companies in the UK, as these typically have higher institutional shareholdings and lower insider holdings, said the Citi report.

Companies within the Netherlands, Germany and Switzerland are at medium risk of being targeted by activists, while those in France, Italy and Spain are deemed to be low risk because of their shareholder structures, which have high levels of family and regional bank ownership.

Christopher Fawcett, senior investment officer at Permal Investment Management, which launched a fund of activist funds in September, said: "In most cases in asset management, things start in the US and then come across the Atlantic. The first stage is the UK and then it’s more widespread."

He added: "The key for US activists in Europe is who else is on the shareholder register. The more disparate it is and the more owned by non-domestic shareholders such as US mutual funds, the happier the activist will be. He will feel like he has a better chance than if the company is predominantly owned by domestic investors."

In economically patriotic countries such as France and Italy the establishment is more likely to close ranks against foreign investors. For example, the French government drafted a law to protect from takeover companies in so-called "strategic industries" such as food products company Danone. This has been dubbed the "Danone law".

A partner at a London-based event-driven hedge fund said: "In Europe, you pick your fights according to the odds. There’s no point fighting against the establishment. You have to look at the context, the local preferences, the history of the company, the stuff that hurts. You can’t just look at the merits of the case."

The US domestic approach to activism is audacious, public and pulls no punches. Rarely a day goes by in the US without a prominent activist lambasting a rival or a target’s management in the pages of the Wall Street Journal. This is epitomised by the public spat between Ackman and Icahn over Herbalife, a global nutrition company, where Ackman has a short position because he thinks it’s a "pyramid scheme", while Icahn has a long position because he thinks it’s "meaningfully undervalued".

On August 13, Icahn took to social media site Twitter to reveal his stake in Apple and last month he even launched a website – the Shareholders’ Square Table – to vent his views.

US company law means that activism in the country depends on publicity. Zimmerman said: "In the US, because the power of the board and the chief executive is very strong and shareholder rights are pretty limited, activist funds tend to be more hostile, whereas in Europe, particularly northern Europe, there is scope to work with boards."

Europe is characterised by a softer approach. UK shareholders with a 5% position can nominate someone to the board. Stephen Cohen, chief executive of Governance for Owners, which calls itself a "responsible activist," said: "We try to be discreet. A great engagement for us is one you’ve never heard of. We don’t want to be on the front page of the [Financial Times]. We think that in Europe clients are best served if we’re not aggressive."

He added: "European company law is more in favour of the shareholder and therefore companies are more predisposed to listen. In the US you have to go public; you’ve set up an adversarial situation almost to begin with."

Citi’s report suggests that in Europe, nearly 45% of all campaign activity is private.

Chris Young, head of the contested situations practice at Credit Suisse, said that an uptick in activism in Europe is likely to be led by US managers. He said: "Although their natural state is maybe too aggressive for European taste, they are smart enough to learn that when in Rome, you should do as the Romans." He said he expects to see US activist campaigns "customised for a European audience".

US investors are also likely to find that activism in Europe comes with more reputational baggage.  Nixon said: "Activism is still not as accepted in Europe as it is in the US. Some UK companies still treat activists as upstart investors who are not welcome at the party."

The event-driven partner said: "In France, Germany, Italy and Spain, activists are seen as locusts." He added that memories are still fresh of ABN Amro, where activist investor TCI successfully called for a break-up but three of the banks that bought the fragments of ABN – Fortis, Royal Bank of Scotland and Monte dei Paschi di Siena – needed a state bailout. He said: "Hedge funds made tons of money from it but the regulators were left to pick up the pieces."

(BFW) Conti Says Enel Debt to Fall to EU40b by Year End: Radio 24

+------------------------------------------------------------------------------+

BN 11/11 08:35 *CONTI SAYS ENEL DEBT TO FALL TO EU40B BY YEAR END: RADIO 24

+------------------------------------------------------------------------------+

Conti Says Enel Debt to Fall to EU40b by Year End: Radio 24 2013-11-11 08:40:09.919 GMT

By Andrew Frye Nov. 11 (Bloomberg) -- Enel CEO says debt to fall from EU44b in interview broadcast by Radio 24 today. * NOTE: Enel Earnings Q3 2013 Earnings Call Teleconference, see screen 6 for net debt figure {NSN MVWNY70J1HL5 <go>}

Link to Company News:{ENEL IM <Equity> CN <GO>}

For Related News and Information: First Word scrolling panel: {FIRST<GO>} First Word newswire: {NH BFW<GO>}

To contact the reporter on this story: Andrew Frye in Rome at +39-06-4520-6322 or afrye@bloomberg.net

To contact the editor responsible for this story: Dan Liefgreen at +39-02-8064-4204 or dliefgreen@bloomberg.net

FT : Renault-Nissan admits it will miss 2016 electric car target

Global sales of electric cars are more than four years behind expectations, Carlos Ghosn of Renault-Nissan said, as he admitted for the first time that the industry leader would miss its targets for the new generation of vehicle. Mr Ghosn, speaking in an interview with the Financial Times, conceded that the market is failing to live up to his expectations. As chief executive of both Renault and Nissan, Mr Ghosn has ploughed billions of dollars into electric vehicles and become their most outspoken cheerleader.

Renault and Nissan, which operate in a global alliance, had previously said they would sell 1.5m electric cars between them by the end of 2016. “We will not be there,” Mr Ghosn said. “At the speed right now, I’m seeing it more four or five years later.” Despite much fanfare, heavy investment and pressure from governments on carmakers to promote low-emission vehicles, electric cars have so far proved costly to build, tough to sell and crippled by limited mileage and a lack of charging infrastructure in key markets – so-called “range anxiety”. Renault and Nissan have together sold more than 120,000 electric cars over the past five years, more than any other manufacturer. Nissan’s Leaf model is the world’s best-selling electric car, with about 85,000 sales so far. But a failure to create charging and support infrastructure for the vehicles has crippled early sales and forced the company to pare back its expectations. “We have to admit, it is slower than we thought. But it is slower for the reason that we thought infrastructure building would be faster. It is not,” Mr Ghosn said.

In markets such as Norway or the state of California in the US, healthy government incentives for buyers and a widespread network of charging points has spurred demand for electric vehicles. I don’t think the main issue today is the cost of the car. The main issue is infrastructure. I would not buy a gasoline car if there were no gasoline stations - Carlos Ghosn, chief executive of Renault and Nissan While rivals General Motors, Honda and Mitsubishi have all developed electric cars, and smaller companies such as Tesla Motors have had some success with battery-only models, Renault-Nissan’s commitment has made it a trailblazer within the industry. But analysts say the decision of Volkswagen and BMW, which unveiled its first electric model this autumn, to enter the developing market could accelerate sales growth. “Today there is nobody, but they are coming,” said Mr Ghosn of competition in the electric car market. “Some of our German competitors have announced that they are coming. They will be our main competitors. And that’s about it. Others have announced one car here, one car there.” The Franco-Japanese alliance announced an agreement with Mitsubishi last week that will see the three companies work together on a small electric car to be sold globally, which is expected to further reduce costs of the technology.

(BFW) Moncler Targets Free Float of ~30% Post Greenshoe: Terms

+------------------------------------------------------------------------------+

Moncler Targets Free Float of ~30% Post Greenshoe: Terms 2013-11-11 07:20:10.16 GMT

By Francesca Cinelli Nov. 11 (Bloomberg) -- Moncler targets free float of ~30% post greenshoe, according to terms of IPO of ordinary shrs (100% secondary). * Current shrhlder structure: Eurazeo (45%), Ruffini Partecipazioni (32%), Carlyle (18%), Brands Partners (5%), S. Buongiovanni (0.3%) * Selling shrhlders: Eurazeo, Carlyle, Brands Partners * Joint global coordinators & joint bookrunners: BofAML, Goldman, Mediobanca * Joint bookrunners: Banca IMI, JPMorgan, Nomura, UBS * Joint lead managers: BNP Paribas, Equita, HSBC * NOTE from Nov. 7: Moncler said to start presentations next week for Italy IPO

Link to Company News:PEF1873 US <Equity> CN <GO> Link to Company News:2942075Z IM <Equity> CN <GO>

For Related News and Information: First Word scrolling panel: FIRST<GO> First Word newswire: NH BFW<GO>

To contact the reporter on this story: Francesca Cinelli in Milan at +39-02-80644-252 or fcinelli@bloomberg.net

To contact the editor responsible for this story: James Ludden at +44-20-7673-2645 or jludden@bloomberg.net

>>> Kazakhmys PLC Gives update on ENRC takeover and share repurchase

Kazakhmys PLC Gives update on ENRC takeover and share repurchase - Following settlement of consideration under the ENRC Takeover Offer, Kazakhmys announces that on 8 November 2013 it received U.S.$887,285,879 cash and 77,041,147 Kazakhmys Shares from Eurasian Resources. The 77,041,147 Kazakhmys Shares were repurchased from Eurasian Resources for £206,516,265 in aggregate which was settled by way of net settlement pursuant to the terms of the Share Repurchase Agreement. The repurchased shares will be cancelled and none will be held as treasury shares.

- Following the above purchase, Kazakhmys has 458,379,033 ordinary shares in issue. Kazakhmys holds 11,701,830 ordinary shares in treasury and the issued share capital of Kazakhmys which carries voting rights of one vote per share comprises 446,677,203 ordinary shares (excluding treasury shares).

- The above figure of 446,677,203 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Kazakhmys under the Disclosure and Transparency Rules.

- Capitalised terms used in this announcement but not otherwise defined herein shall have the same meanings given in the Kazakhmys prospectus dated 7 August 2013.

>>> Novartis agrees to divest blood transfusion diagnostics unit to Grifols for

Novartis agrees to divest blood transfusion diagnostics unit to Grifols for USD 1.675bn

Novartis announced a definitive agreement to divest its blood transfusion diagnostics unit to Grifols for USD 1.675bn. This transaction, requiring customary regulatory approvals, is expected to be completed in the first half of 2014.

"The sale of the Novartis blood transfusion diagnostics unit enables us to focus more sharply on our strategic businesses while providing Grifols with a platform for global expansion," said Joseph Jimenez CEO of Novartis. "I am especially pleased that the agreement with Grifols provides our associates with an opportunity to join a company that will focus on growing this business aggressively."

Acquired in 2006 as part of Chiron, the blood transfusion diagnostics unit has formed part of Novartis Vaccines and Diagnostics. The blood transfusion diagnostics unit is dedicated to increasing transfusion safety worldwide with nucleic acid testing, blood testing products and immunoassay reagents that detect infectious disease. Headquartered in Emeryville, California, its net sales in 2012 were approximately USD 565m. Not included in the sale is the Novartis companion diagnostics unit that is integrated into the pharmaceuticals business, nor the Genoptix business, as these are closely linked to the pharmaceuticals pipeline.

Headquartered in Barcelona, Spain, Grifols is the world's third largest producer of plasma-derived therapies.